Board Committees

Todd Wider, MD. has served on our board of directors since October 2021. Todd is the Executive Chairman and Chief Medical Officer of Emendo Biotherapeutics, which focuses on highly specific and differentiated next generation gene editing. Todd previously consulted with a number of entities in the biotechnology industry and has served on numerous boards of directors during his career. Todd is an active, honorary member of the medical staff of Mount Sinai Hospital in New York, where he worked for over 20 years, focused on reconstructive surgery. Todd received an MD from Columbia College of Physicians and Surgeons, where he was Rudin Fellow, and an AB, with high honors and Phi Beta Kappa, from Princeton University. Todd did his residency in general surgery and plastic and reconstructive surgery at Columbia Presbyterian Medical Center, and postdoctoral fellowships in complex reconstructive surgery at Memorial Sloan Kettering Cancer Center, where he was Chief Microsurgery Fellow, and in craniofacial surgery at the University of Miami. Todd is also a principal in Wider Film Projects, a documentary film company focused on producing films with sociopolitical resonance that have won Academy, Emmy and Peabody Awards.

Josh Donfeld has served on our board of directors since October 2021.  He has had more than 20 years experience on Wall Street investing in multiple industries.  Most recently Josh was a co-founding and co-managing partner of Castle Hook Partners, a New York-based investment management fund where he was responsible for overseeing the fund’s equity investments in sectors such as healthcare and natural resources. Prior to Castle Hook, Josh was a portfolio manager at Soros Fund Management where he was responsible for managing a portfolio of assets across public and private investments in industries spanning Energy, Utilities, Materials, Industrials, Healthcare, Consumer, Infrastructure and Technology. Josh has extensive experience in early-stage investing and he has extensive experience in management, corporate finance and accounting. Josh graduated Magna Cum Laude from Princeton University with a BA in Economics and a focus on Chinese language/East Asian Studies.

Duncan Moore, Ph.D. has served on our board of directors since October 2021. Duncan is a partner at East West Capital Partners since May 2008, which has a focus on making investments in the Healthcare Industry in Asia. Previously, from 1991 to 2008, Duncan was a top-ranked pharmaceutical analyst at Morgan Stanley leading the firm’s global healthcare equity research team. Duncan was educated in Edinburgh and went to the University of Leeds where he studied Biochemistry and Microbiology. He has a M.Phil. and Ph.D. from the University of Cambridge where he was also a post-doctoral research fellow.

Duncan Moore, Ph.D. has served on our board of directors since October 2021. Duncan is a partner at East West Capital Partners since May 2008, which has a focus on making investments in the Healthcare Industry in Asia. Previously, from 1991 to 2008, Duncan was a top-ranked pharmaceutical analyst at Morgan Stanley leading the firm’s global healthcare equity research team. Duncan was educated in Edinburgh and went to the University of Leeds where he studied Biochemistry and Microbiology. He has a M.Phil. and Ph.D. from the University of Cambridge where he was also a post-doctoral research fellow.

Todd Wider, MD. has served on our board of directors since October 2021. Todd is the Executive Chairman and Chief Medical Officer of Emendo Biotherapeutics, which focuses on highly specific and differentiated next generation gene editing. Todd previously consulted with a number of entities in the biotechnology industry and has served on numerous boards of directors during his career. Todd is an active, honorary member of the medical staff of Mount Sinai Hospital in New York, where he worked for over 20 years, focused on reconstructive surgery. Todd received an MD from Columbia College of Physicians and Surgeons, where he was Rudin Fellow, and an AB, with high honors and Phi Beta Kappa, from Princeton University. Todd did his residency in general surgery and plastic and reconstructive surgery at Columbia Presbyterian Medical Center, and postdoctoral fellowships in complex reconstructive surgery at Memorial Sloan Kettering Cancer Center, where he was Chief Microsurgery Fellow, and in craniofacial surgery at the University of Miami. Todd is also a principal in Wider Film Projects, a documentary film company focused on producing films with sociopolitical resonance that have won Academy, Emmy and Peabody Awards.

Josh Donfeld has served on our board of directors since October 2021.  He has had more than 20 years experience on Wall Street investing in multiple industries.  Most recently Josh was a co-founding and co-managing partner of Castle Hook Partners, a New York-based investment management fund where he was responsible for overseeing the fund’s equity investments in sectors such as healthcare and natural resources. Prior to Castle Hook, Josh was a portfolio manager at Soros Fund Management where he was responsible for managing a portfolio of assets across public and private investments in industries spanning Energy, Utilities, Materials, Industrials, Healthcare, Consumer, Infrastructure and Technology. Josh has extensive experience in early-stage investing and he has extensive experience in management, corporate finance and accounting. Josh graduated Magna Cum Laude from Princeton University with a BA in Economics and a focus on Chinese language/East Asian Studies.

Duncan Moore, Ph.D. has served on our board of directors since October 2021. Duncan is a partner at East West Capital Partners since May 2008, which has a focus on making investments in the Healthcare Industry in Asia. Previously, from 1991 to 2008, Duncan was a top-ranked pharmaceutical analyst at Morgan Stanley leading the firm’s global healthcare equity research team. Duncan was educated in Edinburgh and went to the University of Leeds where he studied Biochemistry and Microbiology. He has a M.Phil. and Ph.D. from the University of Cambridge where he was also a post-doctoral research fellow.

Sergey Vasnetsov has served on our board of directors since October 2021. Since 2016 he is the founder of ChemBridges, strategy consulting firm. During 2010-16 he was Senior VP of Strategic Planning and Transactions at LyondellBasell (NYSE: LYB). Prior to that, Sergey was a Managing Director, Equity Research at Barclays Capital and Lehman Brothers. He started his career at Union Carbide in 1990. Sergey has a Master of Science in Catalysis from the Novosibirsk University, Russia. He was a George Soros Scholar at Oxford University (UK) and later earned an MBA in Finance from Rutgers University (US).